First France, Now Germany Pulls Takeda's Actos For New Patients On Bladder Cancer Risk
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda Pharmaceutical Co. bestseller Actos has been withdrawn for new patients in France and Germany due to a long-suspected bladder cancer risk. Besides shrinking some of the excitement around the European boost Takeda received with its acquisition of Nycomed AS, the withdrawals also call into question the remaining revenue Actos can generate before its main patents expire
You may also be interested in...
As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position
For a company like Hikma Pharmaceuticals PLC with over half of its business operating in the Middle East and North Africa, the first half of 2011 has been a challenging time. The political instability in many countries, especially in Egypt and Tunisia, has hurt Hikma's growth and profitability in the first six months
As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position
For a company like Hikma Pharmaceuticals PLC with over half of its business operating in the Middle East and North Africa, the first half of 2011 has been a challenging time. The political instability in many countries, especially in Egypt and Tunisia, has hurt Hikma's growth and profitability in the first six months
As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position
For a company like Jordan-based Hikma Pharmaceuticals PLC with over half of its business operating in the Middle East and North Africa, the first half of 2011 has been a challenging time.